Biotheus pipeline
WebJun 1, 2024 · Alligator's pipeline includes five lead clinical and preclinical drug candidates: mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical ... WebMar 3, 2024 · This is supported by the company’s product pipeline, which consists of over 10 novel monoclonal and multispecific antibodies. Biotheus currently has two bispecific antibodies in phase I clinical development for cancer treatment, and a third IND application was submitted at the end of 2024.
Biotheus pipeline
Did you know?
WebAlligators Bioscience’s portfolio comprise the drug candidates mitazalimab, ATOR-1017 and ALG.APV-527, as well as the drug concept Neo-X-Prime™, all of which are intended for the treatment of metastatic cancers. The … WebFounded Date 2024. Founders Andy Tsun, Joanne Sun, Xiaolin Liu. Operating Status Active. Last Funding Type Series B. Also Known As 普米斯, Pumis Bio. Legal Name Biotheus Inc. Company Type For Profit. …
WebDec 4, 2024 · Category: Antibodies. Published on Saturday, 04 December 2024 11:35. Hits: 1443. ZHUHAI, China I December 3, 2024 I Biotheus Inc., has announced that its … WebBiotheus has constructed a product pipeline of over 10 national innovative biological drugs, of which 2 new antibody drugs have been approved for clinical trial. According to product development plan, 5 new antibody …
WebJan 27, 2024 · Biotheus’ management team has broad experience from drug discovery to NDA filing in China and is developing a broad me-better/novel target pipeline focused on immuno-oncology and metabolic diseases. WebIt natively comes with conventional UT, TOFD and all beam-forming phased array UT techniques for single-beam and multi-group inspection and its 3-encoded axis …
WebIn our pipeline, our lead therapeutic asset, TILT-123, is a cytokine armed oncolytic adenovirus that is currently in Phase 1 clinical trials as monotherapy and in combination with tumor infiltrating lymphocytes (TIL) therapy in Europe. ... MSD International GmbH, and Biotheus, a privately held Chinese biotechnology company.
WebApr 14, 2024 · Recently Concluded Data & Programmatic Insider Summit March 22 - 25, 2024, Scottsdale Digital OOH Insider Summit February 19 - 22, 2024, La Jolla diddy the jokerWebClinical pipeline. TILT’s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human T- cell stimulating cytokines; TNF alpha and IL-2. ... In 2024, TILT established an additional partnership with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China, for the development and commercialization of ... diddy surprises mom with 1 million checkWebNov 15, 2024 · With a well-seasoned development team, Biotheus has built up a robust pipeline inclusive of 10 programs at different stages of clinical development. For more information about Biotheus, please ... diddy the rapperWebBiotheus General Information. Description. Developer of next generation antibody-based therapeutics. The company studies the mechanisms of TReg cells and innate immunity in cancer, discovers antibody and develops antibody-based therapeutics, enabling patients to have more efficient immunity therapy and drugs for cancer and metabolic diseases. diddy talent showWebAug 20, 2024 · Biotheus is developing a broad me-better/novel target pipeline focused on immuno-oncology and metabolic disease areas, with the aim to develop their leading assets towards market authorization. Biotheus is actively looking for late-stage clinical and commercialization partners to fulfill these aims. diddy the saga continuesWebNov 7, 2024 · MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. Utilizing the Life Science business … diddy toysWebNational Center for Biotechnology Information diddy tribute to kim porter